Skip to content

Clinical observation of  moxibustion with seed-sized moxa cone combined with traditional Chinese and Western medicine in the treatment of senile acute

Clinical observation of  moxibustion with seed-sized moxa cone combined with traditional Chinese and Western medicine in the treatment of senile acute

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2023000041
Enrollment
Unknown
Registered
2023-09-03
Start date
2023-09-05
Completion date
Unknown
Last updated
2023-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Senile acute myeloid leukemia

Interventions

moxibustion with seed-sized moxa cone treatment group:Moxibustion with seed-sized moxa cone treatment: Main point:Dazhui Ke shu Pi' shu Shen shu Tsusanli Matching acupoint:Chungwan (Nausea, vomiting

Sponsors

Xi Yuan Hospital of China Academy of Chinese Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
60 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Patients who meet the diagnostic criteria for AML; (2)Patients over the age of 60 (3) The patient was generally in good condition, with a KPS score of 60; (4) Patients admitted to the hospital for chemotherapy; (5) The expected survival period is greater than 3 months; (6) The patient participated voluntarily and signed an informed consent form.

Exclusion criteria

Exclusion criteria: (1) Patients with central nervous system leukemia; (2) Patients with platelet count less than 10109 / L; (3) Skin damage and other reasons are not suitable for moxibustion; (4) With severe organ function injury and other complications, it cannot tolerate chemotherapy; (5) Mental abnormalities and other circumstances can not cooperate.

Design outcomes

Primary

MeasureTime frame
Peripheral white blood cell count;

Secondary

MeasureTime frame
Peripheral blood neutrophils\platelet\hemoglobin;Coagulation function\c-reactive protein;Interval and rate of rechemotherapy;Major symptom score;Amount of blood transfused during treatment (including red cell suspension and platelet collection);Percentage of bone marrow original cells;Incidence of infection and bleeding (urinary, digestive, oral, nasal) in patients during chemotherapy;KarnofskyPerformance Status;Bone marrow original cell count;

Countries

China

Contacts

Public ContactMa Yun

Xi Yuan Hospital of China Academy of Chinese Medical Sciences

mayun0213@sohu.com18611792355

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026